본문 바로가기
KERD
논문KCI 등재

Outcome of COVID-19 Infection in Patients With Multiple Sclerosis Who Received Disease-Modifying Therapies: A Systematic Review and Meta-Analysis

Jing Sun|Ning Liu|WuHan Yu|Mengjiao Sun|Wenjing Zhang|Dan Zhou|ManXia Wang
대한신경과학회 (Korean Neurological Association)|2023.07|Journal of Clinical Neurology|제19권 제4호|pp. 381-391

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

COVID-19prognosismultiple sclerosisdisease-modifying therapies

초록

Background and Purpose A systematic review and meta-analysis was performed of the outcome of Coronavirus disease 2019 (COVID-19) infection in patients with multiple sclerosis (MS) who received disease-modifying therapies (DMTs). Methods Relevant studies published before November 2022 in the PubMed, Cochrane Library, Chinese National Knowledge Infrastructure, and Web of Science databases were retrieved using the following search expression: (“multiple sclerosis” OR “MS”) AND (“DMT” OR “disease modifying therapies”) AND (“COVID-19”). Two authors independently screened the articles and extracted the data. Qualitative analyses and a meta-analysis constituted 22 of the 794 retrieved articles. Differences in the hospitalization and mortality rates were used as the main measures of efficacy, and the meta-analysis was performed using RevMan software. Results 22 clinical trials were selected. The hospitalization rate was lower in the 3,216 patients who received DMTs than in the 774 patients who did not receive any treatment, with a moderate effect size of 0.43 (p<0.00001). The mortality rate was also lower among patients with MS treated using DMTs than in controls (odds ratio [OR]=0.19, 95% confidence interval [CI]=0.13–0.27, p<0.00001). The hospitalization rates for COVID-19 infection in patients with MS treated with anti-CD20 therapy also increased markedly (OR=3.32, 95% CI=2.63–4.20, p<0.00001). However, there was no significant difference between patients with MS who did and did not receive DMTs. Conclusions In summary, the application of DMTs was found to be valuable for patients with MS infected with COVID-19. However, more clinical studies are needed to determine the use of anti-CD20 drugs in patients with MS during the COVID-19 pandemic.

Abstract

Background and Purpose A systematic review and meta-analysis was performed of the outcome of Coronavirus disease 2019 (COVID-19) infection in patients with multiple sclerosis (MS) who received disease-modifying therapies (DMTs). Methods Relevant studies published before November 2022 in the PubMed, Cochrane Library, Chinese National Knowledge Infrastructure, and Web of Science databases were retrieved using the following search expression: (“multiple sclerosis” OR “MS”) AND (“DMT” OR “disease modifying therapies”) AND (“COVID-19”). Two authors independently screened the articles and extracted the data. Qualitative analyses and a meta-analysis constituted 22 of the 794 retrieved articles. Differences in the hospitalization and mortality rates were used as the main measures of efficacy, and the meta-analysis was performed using RevMan software. Results 22 clinical trials were selected. The hospitalization rate was lower in the 3,216 patients who received DMTs than in the 774 patients who did not receive any treatment, with a moderate effect size of 0.43 (p<0.00001). The mortality rate was also lower among patients with MS treated using DMTs than in controls (odds ratio [OR]=0.19, 95% confidence interval [CI]=0.13–0.27, p<0.00001). The hospitalization rates for COVID-19 infection in patients with MS treated with anti-CD20 therapy also increased markedly (OR=3.32, 95% CI=2.63–4.20, p<0.00001). However, there was no significant difference between patients with MS who did and did not receive DMTs. Conclusions In summary, the application of DMTs was found to be valuable for patients with MS infected with COVID-19. However, more clinical studies are needed to determine the use of anti-CD20 drugs in patients with MS during the COVID-19 pandemic.

참고문헌 (53)

  1. Wu C, "Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China", JAMA Intern Med, 180, pp.934~943 (2020)
  2. Garg N, "An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis", Brain Behav, 5, pp.e00362~ (2015)
  3. Seery N, "Evaluating the perspective of patients with MS and related conditions on their DMT in relation to the COVID-19 pandemic in one MS centre in Australia", Mult Scler Relat Disord, 46, pp.102516~ (2020)
  4. Saltonstall L, "Reader response : practice guideline recommendations summary : disease-modifying therapies for adults with multiple sclerosis : report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology", Neurology, 92, pp.109~110 (2019)
  5. Sormani MP, "Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies", EBioMedicine, 72, pp.103581~ (2021)
  6. Simpson-Yap S, "Associations of disease-modifying therapies with COVID-19severity in multiple sclerosis", Neurology, 97, pp.e1870~e1885 (2021)
  7. Louapre C, "Anti-CD20 therapies decrease humoral immune response to SARSCoV-2 in patients with multiple sclerosis or neuromyelitis optica spectrum disorders", J Neurol Neurosurg Psychiatry, 93, pp.24~31 (2022)
  8. Ju B, "Human neutralizing antibodies elicited by SARS-CoV-2 infection", Nature, 584, pp.115~119 (2020)
  9. Sormani MP, "Disease-modifying therapies and coronavirus disease 2019 severity in multiple sclerosis", Ann Neurol, 89, pp.780~789 (2021)
  10. Giovannoni G, "The COVID-19 pandemic and the use of MS disease-modifying therapies", Mult Scler Relat Disord, 39, pp.102073~ (2020)
  11. Zheng C, "Multiple sclerosis disease-modifying therapy and the COVID-19 pandemic : implications on the risk of infection and future vaccination", CNS Drugs, 34, pp.879~896 (2020)
  12. Novi G, "COVID-19 in a MS patient treated with ocrelizumab : does immunosuppression have a protective role?", Mult Scler Relat Disord, 42, pp.102120~ (2020)
  13. Montero-Escribano P, "Anti-CD20 and COVID-19 in multiple sclerosis and related disorders : a case series of 60 patients from Madrid, Spain", Mult Scler Relat Disord, 42, pp.102185~ (2020)
  14. Louapre C, "Clinical characteristics and outcomes in patients with coronavirus disease 2019 and multiple sclerosis", JAMA Neurol, 77, pp.1079~1088 (2020)
  15. Bsteh G, "COVID-19 severity and mortality in multiple sclerosis are not associated with immunotherapy : insights from a nation-wide Austrian registry", PLoS One, 16, pp.e0255316~ (2021)
  16. Mehta P, "COVID-19 : consider cytokine storm syndromes and immunosuppression", Lancet, 395, pp.1033~1034 (2020)
  17. Parrotta E, "COVID-19 outcomes in MS : observational study of early experience from NYU multiple sclerosis comprehensive care center", Neurol Neuroimmunol Neuroinflamm, 7, pp.e835~ (2020)
  18. Chaudhry F, "COVID-19 in multiple sclerosis patients and risk factors for severe infection", J Neurol Sci, 418, pp.117147~ (2020)
  19. Kister I, "Cellular and humoral immunity to SARS-CoV-2 infection in multiple sclerosis patients on ocrelizumab and other disease-modifying therapies : a multi-ethnic observational study", Ann Neurol, 91, pp.782~795 (2022)
  20. Reder AT, "COVID-19 in patients with multiple sclerosis : associations with disease-modifying therapies", CNS Drugs, 35, pp.317~330 (2021)
  21. Loonstra FC, "COVID-19 in multiple sclerosis : the Dutch experience", Mult Scler, 26, pp.1256~1260 (2020)
  22. Arrambide G, "SARS-CoV-2 infection in multiple sclerosis : results of the Spanish Neurology Society registry", Neurol Neuroimmunol Neuroinflamm, 8, pp.e1024~ (2021)
  23. Bowen JD, "COVID-19 in MS : initial observations from the Pacific Northwest", Neurol Neuroimmunol Neuroinflamm, 7, pp.e783~ (2020)
  24. Spelman T, "Increased rate of hospitalisation for COVID-19 among rituximab-treated multiple sclerosis patients : a study of the Swedish multiple sclerosis registry", Mult Scler, 28, pp.1051~1059 (2022)
  25. Pistor M, "Multiple sclerosis immunotherapies and COVID-19 mortality : an analysis of the FDA adverse event reporting system", Ther Adv Neurol Disord, 15, pp.17562864221129383~ (2022)
  26. Sahraian MA, "Evaluation of the rate of COVID-19 infection, hospitalization and death among Iranian patients with multiple sclerosis", Mult Scler Relat Disord, 46, pp.102472~ (2020)
  27. Maghbooli Z, "Association between disease-modifying therapies and adverse clinical outcomes in multiple sclerosis patients with COVID-19 infection", Mult Scler Relat Disord, 67, pp.104067~ (2022)
  28. Barzegar M, "Risk and severity of SARS-CoV-2 reinfection among patients with multiple sclerosis vs. the general population : a population-based study", BMC Neurol, 22, pp.379~ (2022)
  29. Ciampi E, "COVID-19 in MS and NMOSD : a multicentric online national survey in Chile", Mult Scler Relat Disord, 45, pp.102392~ (2020)
  30. Sormani MP, "DMTs and Covid-19 severity in MS : a pooled analysis from Italy and France", Ann Clin Transl Neurol, 8, pp.1738~1744 (2021)
  31. Guerrera G, "Anti-SARS-CoV-2 T-stem cell memory persists in ocrelizumabtreated MS patients", Mult Scler, 28, pp.1937~1943 (2022)
  32. Czarnowska A, "Clinical course and outcome of SARSCoV-2 infection in multiple sclerosis patients treated with diseasemodifying therapies-the Polish experience", Neurol Neurochir Pol, 55, pp.212~222 (2021)
  33. Solomon JM, "Clinical characteristics and outcomes of multiple sclerosis patients with COVID-19 in Toronto, Canada", Mult Scler Relat Disord, 58, pp.103509~ (2022)
  34. Yeo T, "COVID-19 infection after two doses of SARS-CoV-2 mRNA vaccine in multiple sclerosis, AQP4-antibody NMOSD and MOGAD", Mult Scler Relat Disord, 65, pp.104003~ (2022)
  35. Thompson AJ, "Multiple sclerosis", Lancet, 391, pp.1622~1636 (2018)
  36. Prosperini L, "Determinants of COVID-19-related lethality in multiple sclerosis : a meta-regression of observational studies", J Neurol, 269, pp.2275~2285 (2022)
  37. Grebenciucova E, "Infections in patients receiving multiple sclerosis disease-modifying therapies", Curr Neurol Neurosci Rep, 17, pp.88~ (2017)
  38. Matías-Guiu J, "Potential COVID-19 infection in patients with severe multiple sclerosis treated with alemtuzumab", Mult Scler Relat Disord, 44, pp.102297~ (2020)
  39. Yeung AWK, "Reactive oxygen species and their impact in neurodegenerative diseases : literature landscape analysis", Antioxid Redox Signal, 34, pp.402~420 (2021)
  40. Jin Y, "Virology, epidemiology, pathogenesis, and control of COVID-19", Viruses, 12, pp.372~ (2020)
  41. Zheng C, "Real-world effectiveness of COVID-19 vaccines : a literature review and metaanalysis", Int J Infect Dis, 114, pp.252~260 (2022)
  42. Simpson-Yap S, "Updated results of the COVID-19 in MS global data sharing initiative : anti-CD20 and other risk factors associated with COVID-19 severity", Neurol Neuroimmunol Neuroinflamm, 9, pp.e200021~ (2022)
  43. Berger JR, "COVID-19 and MS diseasemodifying therapies", Neurol Neuroimmunol Neuroinflamm, 7, pp.e761~ (2020)
  44. Huang C, "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China", Lancet, 395, pp.497~506 (2020)
  45. Luna G, "Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies", JAMA Neurol, 77, pp.184~191 (2020)
  46. Shi Y, "COVID-19 infection : the perspectives on immune responses", Cell Death Differ, 27, pp.1451~1454 (2020)
  47. Tay MZ, "The trinity of COVID-19 : immunity, inflammation and intervention", Nat Rev Immunol, 20, pp.363~374 (2020)
  48. Giovannoni G, "Anti-CD20 immunosuppressive disease-modifying therapies and COVID-19", Mult Scler Relat Disord, 41, pp.102135~ (2020)
  49. Suwanwongse K, "Benign course of COVID-19 in a multiple sclerosis patient treated with ocrelizumab", Mult Scler Relat Disord, 42, pp.102201~ (2020)
  50. Gelfand JM, "Ocrelizumab and other CD20+B-cell-depleting therapies in multiple sclerosis", Neurotherapeutics, 14, pp.835~841 (2017)
  51. Gingele S, "Ocrelizumab depletes CD20+ T cells in multiple sclerosis patients", Cells, 8, pp.12~ (2018)
  52. Bar-Or A, "Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis : the VELOCE study", Neurology, 95, pp.e1999~e2008 (2020)
  53. Chen Q, "CD3+CD20+ T cells and their roles in human diseases", Hum Immunol, 80, pp.191~194 (2019)

이 간행물의 다른 논문 (16건)

Role of A-Kinase Anchoring Protein 12 in the Central Nervous SystemKen Arai, Eng H. Lo, Irwin H. Gelman, Josephine Lok, Shintaro Kimurapp. 329-337Cerebral Arterial Stiffness as Measured Based on the Pulse Wave Velocity Is Associated With Intracranial Artery Calcification in Patients With Acute StrokeXuelong Li, Jia Li, Xiangyan Chen, Qingchun Gao, Xianliang Li, Heng Dupp. 338-343Risk of Cognitive Impairment in Patients With Parkinson’s Disease With Visual Hallucinations and Subjective Cognitive ComplaintsCOPPADIS Study Group, Maria G. Alonso Losada, Nuria López Ariztegui, Itziar Gastón, Jaime Kulisevsky, Marta Blázquez Estrada, Manuel Seijo, Javier Rúiz Martínez, Caridad Valero, Mónica Kurtis, Oriol de Fábregues, Jessica González Ardura, Ruben Alonso Redondo, Carlos Ordás, Luis M. López Díaz L, Darrian McAfee, Pablo Martinez-Martin, Pablo Mir, Diego Santos-García, Teresa de Deus Fonticoba, Carlos Cores Bartolomé, Maria J. Feal Painceiras, Cristina Martínez Miró, Silvia Jesús, Miquel Aguilar, Pau Pastor, Lluís Planellas, Marina Cosgaya, Juan García Caldentey, Nuria Caballol, Ines Legarda, Jorge Hernández Vara, Iria Cabo, Lydia López Manzanares, Isabel González Aramburu, Maria A. Ávila Rivera, Víctor Gómez Mayordomo, Víctor Nogueira, Víctor Puente, Julio Dotor García-Soto, Carmen Borrué, Berta Solano Vila, María Álvarez Sauco, Lydia Vela, Sonia Escalante, Esther Cubo, Francisco Carrillo Padilla, Juan C. Martínez Castrillo, Pilar Sánchez Alonsopp. 344-357Five-Year Retention of Perampanel and Polytherapy Patterns: 328 Patients From a Single Center in South Korea박경일, 주건, 황성은, 이상건, 정기영, 손효신pp. 358-364Prehospital Levetiracetam Use in Adults With Status Epilepticus: Results of a Multicenter RegistryMarie Madlener, Lothar Burghaus, Volker Limmroth, Emanuel F. Bruno, Felix Kohle, Gereon R. Fink, Michael P. Malterpp. 365-370
원문 보기